<DOC>
	<DOCNO>NCT00691899</DOCNO>
	<brief_summary>The purpose study investigate effect MK0822 prolonging time first bone metastasis men castration-resistant prostate cancer .</brief_summary>
	<brief_title>A Study Assess Effects MK0822 Prolonging Time First Bone Metastasis Men With Castration-Resistant Prostate Cancer ( 0822-030 )</brief_title>
	<detailed_description>Merck Duration Treatment : odanacatib ; approximately 36 month ( even driven study ) - Comparator Duration Treatment : placebo ( unspecified ) ; approximately 36 month ( event driven study )</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Castrationresistant prostate cancer ; increase risk prostate cancer progression Patient underwent bilateral orchiectomy 6 month ( i.e. , =180 day ) prior Visit 1 , receive androgendeprivation therapy stable regimen least 3 month ( i.e. , =90 day ) prior Visit 1 . Androgendeprivation therapy may include gonadotropinreleasing hormone agonist leuprolide , goserelin , triptorelin Bone metastases history bone metastases Patient distant metastasis ( e.g. , visceral , include brain , softtissue ) . Patients regional lymph nodal metastasis eligible Patient ANY following : 1. currently receive bisphosphonate drug therapy osteoporosis 2. treated oral bisphosphonate osteoporosis 3 month within 2 year prior Visit 1 , total 6 month time prior Visit 1 3. treat intravenous bisphosphonate within 12 month prior Visit 1 Patient receive chemotherapy within 2 year prior Visit 1 ( example , doxorubicin , cytoxan , estramustine , paclitaxel , docetaxel , etoposide , vinblastine , 5fluorouracil , interferon , mitoxantrone ) . This exclusion criterion include androgendeprivation therapy ( e.g. , gonadotropinreleasing hormone agonist leuprolide , goserelin , triptorelin ) Patient history malignancy prostate cancer &lt; 5 year prior sign inform consent , except adequately treat basal cell squamous cell skin cancer . Melanoma , leukemia , lymphoma , myeloproliferative disorder duration exclude Patient currently participate , participate study investigational compound device within 30 day sign informed consent Patient currently participate time past participated prostate cancer study register medication ( i.e. , approve regulatory agency resides ) test treatment prostate cancer ( unapproved indication ) Patient currently use systemically administer azole antifungal ( example , ketoconazole , fluconazole , itraconazole , miconazole , posaconazole , ravuconazole , voriconazole ) . Patients take medication must discontinue use least one week prior start blind study medication</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>